文献速递中医内科针灸推拿中药与中成药合理使用

中医药靶向铁死亡对抗脑缺血再灌注损伤的研究进展

Progress of Traditional Chinese Medicine in Targeting Ferroptosis to Combat Cerebral Ischemia-Reperfusion Injury.
PubMed 文献 · Am J Chin Med · 2026-06-08

本综述评估了中医药抗击脑缺血再灌注损伤(CIRI)的效能,聚焦于活性化合物(黄芪甲苷IV、大黄酸、黄芩素、银杏内酯B、小檗碱)、经典方剂(补阳还五汤、通窍活血汤、脑泰方)及针灸疗法。这些干预通过靶向铁死亡关键机制减轻CIRI,包括增强抗氧化防御(Nrf2/SLC7A11/GPX4)、调节脂质代谢(ACSL4)、恢复铁稳态及维持缺血微环境。

要点

  • 中医药通过调控铁死亡通路发挥神经保护作用。
  • 活性化合物、经典方剂和针灸均显示抗CIRI潜力。
  • 机制涉及抗氧化、脂质代谢、铁稳态和微环境维护。

核心结论

  • 中医药主要通过调节铁死亡通路对脑缺血再灌注损伤发挥神经保护作用。

研究设计与样本

  • 综述,评估多种中医药方法(活性化合物、经典方剂、针灸)对抗CIRI的效能。

主要发现

  • 活性化合物如黄芪甲苷IV、大黄酸、黄芩素、银杏内酯B和小檗碱具有抗CIRI作用。
  • 经典方剂如补阳还五汤、通窍活血汤和脑泰方以及针灸疗法可减轻CIRI。
  • 干预措施靶向铁死亡相关机制:增强抗氧化防御(Nrf2/SLC7A11/GPX4)、调节脂质代谢(ACSL4)、恢复铁稳态、维持缺血微环境(血脑屏障完整性和小胶质细胞极化)。

临床怎么用

  • 可考虑将靶向铁死亡的中医药干预用于CIRI神经保护,但需注意方药药理基础不清和量效关系不明的问题。

局限性

  • 对复杂方剂的药理基础认识不足。
  • 剂量-反应关系不明确。
  • 缺乏沿「成分-靶点-表型」连续体的全面验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cerebral ischemia-reperfusion injury (CIRI) often results in significant morbidity and mortality. The effectiveness of current reperfusion therapies is hindered by substantial secondary damage, which highlights the need for novel molecular targets and neuroprotective strategies. Ferroptosis, a form of programmed cell death driven by iron dysregulation and lipid peroxidation, has emerged as a key player in CIRI pathogenesis. Traditional Chinese medicine (TCM) has demonstrated considerable potential in managing IS, and increasing evidence suggests its neuroprotective effects are primarily mediated through modulation of ferroptotic pathways. This review evaluates the efficacy of various TCM approaches in combating CIRI, and offers a specific focus on the roles of active compounds (e.g., astragaloside IV, rhein, baicalein, ginkgolide B, and berberine), classic herbal formulas (e.g., Buyang Huanwu Decoction, Tongqiao Huoxue Decoction, and Naotaifang), and acupuncture therapies. This review outlines how these interventions attenuate CIRI by targeting critical ferroptosis-related mechanisms. These mechanisms include enhancing anti-oxidant defenses (Nrf2/SLC7A11/GPX4), modulating lipid metabolism (ACSL4), restoring iron homeostasis, and maintaining the ischemic microenvironment (including blood-brain barrier integrity and microglial polarization). However, current research faces challenges such as the insufficient understanding of the pharmacological basis of complex formulas, unclear dose-response relationships, and a lack of comprehensive validation along the "ingredient-target-phenotype" continuum. Future research should focus on leveraging advanced technologies - such as network pharmacology, multi-omics, and artificial intelligence - to unravel the antiferroptotic networks of TCM. Such integrative approaches will drive the modernization of TCM and facilitate the development of precision medicine to thus present new opportunities for neuroprotection in CIRI.

来源:Am J Chin Med,查看原文。版权归原作者所有。

引用

  1. Li J, Liu A, Gao W, et al. Progress of Traditional Chinese Medicine in Targeting Ferroptosis to Combat Cerebral Ischemia-Reperfusion Injury. Am J Chin Med. 2026. PMID: 42261256. doi:10.1142/S0192415X26500382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。